Report commissioned by govt analysed cost-effectiveness of 2 medicines, comparing them to to chemo in patients with newly ...

Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Alecensa ...

Alecensa is used to treat non-small-cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. Some types of lung cancer can be treated with a drug that works when it is combined ...

The Food and Drug Administration (FDA) has only approved ceritinib (Zykadia) and lorlatinib (Lorbrena) to treat ALK-positive lung cancer. However, a doctor may still prescribe if you have ROS1 ...

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...

Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic alterations, including EGFR and ALK subgroups. Among patients with advanced ...

Immutep (ASX:IMM) has dosed the first patient in its pivotal Phase III trial evaluating eftilagimod alfa (efti) for the ...

Sydney, Australia Friday, March 28, 2025, 18:00 Hrs [IST] ...